

CORRECTION OPEN



Correction: Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4

Tianzhen Hu, Chengyun Pan, Tianzhuo Zhang, Ming Ni, Weili Wang , Siyu Zhang, Ying Chen, Jishi Wang and Qin Fang

© The Author(s) 2022

Cancer Gene Therapy (2022) 29:1804–1805; <https://doi.org/10.1038/s41417-022-00519-5>Correction to: *Cancer Gene Therapy* <https://doi.org/10.1038/s41417-022-00501-1>, published online 15 July 2022

We have carefully corrected this error, and the corrected Table 2 is as shown above.

In Table 2 of this article, the data in the Table 2 headed Nrf2 overexpression increases cytarabine resistance in acute myeloid leukemia through inhibition of replication factor C4 were mistakenly listed under the table 2.

The original article has been corrected.

Table 2. Sample characteristics at before relapse (newly diagnosed) and relapse in the same AML patient ($n = 15$).

		Before relapse	Relapse	P Value
WBC ($\times 10^9/L$)	Median	13.74	15.44	0.736
	Range	2.11–223.39	0.66–185.89	
HB ($\times 10^9/L$)	Median	79.00	94.00	0.580
	Range	44.00–129.00	23.00–129.00	
PLT ($\times 10^9/L$)	Median	51.00	24.00	0.623
	Range	4.00–346.00	6.00–402.00	
RBC ($\times 10^9/L$)	Median	2.25	2.63	0.415
	Range	1.27–4.06	1.27–3.85	
BM Blast (%)	Median	42.00	71.75	0.073
	Range	21.29–93.57	22.06–92.14	
Gene mutation	Mutation	4 (26.7%)	6 (40%)	0.456
	No mutation	11 (73.4%)	9 (60%)	

BM bone marrow, HB hemoglobin, PLT platelet and WBC white blood cell, RBC red blood cell.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022